These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 10081698)

  • 1. Role of neoadjuvant treatment in clinically confined prostate cancer. Takeda NHT Italian Group.
    Prezioso D; Lotti T; Montironi R; Polito M
    Eur Urol; 1999; 35 Suppl 1():17-21; discussion 22. PubMed ID: 10081698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leuprorelin 1-month depot as neoadjuvant therapy for prostate cancer. Takeda NHT Italian Group.
    Prezioso D; Lotti T; Montironi R; Polito M
    Urol Int; 1998; 60 Suppl 2():11-7; discussion 35. PubMed ID: 9607553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathologic effects of neoadjuvant cyproterone acetate on nonneoplastic prostate, prostatic intraepithelial neoplasia, and adenocarcinoma: a detailed analysis of radical prostatectomy specimens from a randomized trial.
    Bullock MJ; Srigley JR; Klotz LH; Goldenberg SL
    Am J Surg Pathol; 2002 Nov; 26(11):1400-13. PubMed ID: 12409716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of total androgen ablation on pathologic stage and resection limit status of prostate cancer. Initial results of the Italian PROSIT study.
    Montironi R; Diamanti L; Santinelli A; Galetti-Prayer T; Zattoni F; Selvaggi FP; Pagano F; Bono AV
    Pathol Res Pract; 1999; 195(4):201-8. PubMed ID: 10337657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of combination endocrine treatment on normal prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma.
    Montironi R; Magi-Galluzzi C; Muzzonigro G; Prete E; Polito M; Fabris G
    J Clin Pathol; 1994 Oct; 47(10):906-13. PubMed ID: 7525657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
    Fair WR; Betancourt JE
    Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction androgen deprivation plus prostatectomy for stage T3 disease: failure to achieve prostate-specific antigen-based freedom from disease status in a phase II trial.
    Gomella LG; Liberman SN; Mulholland SG; Petersen RO; Hyslop T; Corn BW
    Urology; 1996 Jun; 47(6):870-7. PubMed ID: 8677579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of complete androgen blockade on pathologic stage and resection margin status of prostate cancer: progress pathology report of the Italian PROSIT study.
    Bono AV; Pagano F; Montironi R; Zattoni F; Manganelli A; Selvaggi FP; Comeri G; Fiaccavento G; Guazzieri S; Selli C; Lembo A; Cosciani-Cunico S; Potenzoni D; Muto G; Diamanti L; Santinelli A; Mazzucchelli R; Prayer-Galletti T;
    Urology; 2001 Jan; 57(1):117-21. PubMed ID: 11164155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant hormone treatment with leuprolide acetate depot 3.75 mg and cyproterone acetate, before radical prostatectomy: a randomized study.
    Prezioso D; Lotti T; Polito M; Montironi R
    Urol Int; 2004; 72(3):189-95. PubMed ID: 15084760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No residual tumor in a radical prostatectomy specimen after neoadjuvant hormonal therapy for localized prostate cancer.
    Noguchi M; Noda S; Nakashima O; Kojiro M
    Oncol Rep; 2002; 9(5):1075-80. PubMed ID: 12168076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative study of the impact of 3- versus 8-month neoadjuvant hormonal therapy on outcome of laparoscopic radical prostatectomy.
    Pu XY; Wang XH; Wu YL; Wang HP
    J Cancer Res Clin Oncol; 2007 Aug; 133(8):555-62. PubMed ID: 17457611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant hormonal therapy and radical prostatectomy for clinical stage C carcinoma of the prostate.
    Narayan P; Lowe BA; Carroll PR; Thompson IM
    Br J Urol; 1994 May; 73(5):544-8. PubMed ID: 8012777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of pathological stage before neoadjuvant androgen withdrawal therapy and radical prostatectomy. The Canadian Urologic Oncology Group.
    Rabbani F; Goldenberg SL; Klotz LH
    J Urol; 1998 Mar; 159(3):925-8. PubMed ID: 9474184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant hormonal therapy prior to radical prostatectomy: the European experience.
    Debruyne FM; Witjes WP
    Mol Urol; 2000; 4(3):251-6;discussion 257. PubMed ID: 11062381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation.
    Matsushima H; Goto T; Hosaka Y; Kitamura T; Kawabe K
    Cancer; 1999 Apr; 85(8):1822-7. PubMed ID: 10223578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of complete androgen blockade for 12 and 24 weeks on the pathological stage and resection margin status of prostate cancer.
    Selli C; Montironi R; Bono A; Pagano F; Zattoni F; Manganelli A; Selvaggi FP; Comeri G; Fiaccavento G; Guazzieri S; Lembo A; Cosciani-Cunico S; Potenzoni D; Muto G; Mazzucchelli R; Santinelli A;
    J Clin Pathol; 2002 Jul; 55(7):508-13. PubMed ID: 12101195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term neoadjuvant hormone therapy prior to radical prostatectomy: evaluation of risk for biochemical recurrence at 5-year follow-up.
    Gleave ME; La Bianca SE; Goldenberg SL; Jones EC; Bruchovsky N; Sullivan LD
    Urology; 2000 Aug; 56(2):289-94. PubMed ID: 10925096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential response to neoadjuvant hormonal therapy in prostate cancer: Predictive morphological parameters and molecular markers.
    Wang X; Qi M; Zhang J; Sun X; Guo H; Pang Y; Zhang Q; Chen X; Zhang R; Liu Z; Liu L; Hao X; Han B
    Prostate; 2019 May; 79(7):709-719. PubMed ID: 30825345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of the Gleason scoring system after neoadjuvant hormonal therapy.
    Bentley G; Dey J; Sakr WA; Wood DP; Pontes JE; Grignon DJ
    Mol Urol; 2000; 4(3):125-;discussion 131. PubMed ID: 11062366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Laparoscopic radical prostatectomy after neoadjuvant hormonal therapy: an apparently safe and effective procedure.
    Brown JA; Garlitz C; Strup SE; Hubosky SG; Gomella L
    J Laparoendosc Adv Surg Tech A; 2004 Dec; 14(6):335-8. PubMed ID: 15684777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.